HeartBeam Accelerates Heart Attack Detection Program, Expands Commercial Footprint
Event summary
- Completed enrollment in ALIGN-ACS pilot study ahead of schedule, with data analysis underway for presentation at TCT 2026.
- Surpassed 50% enrollment in HEADSTART-ACS pilot study in Indonesia, a strategically significant market of 280 million people.
- Completed working prototype of 12-lead ECG extended wear patch and initiated pilot study in Serbia.
- Advanced initial commercial launch for arrhythmia assessment, signing multiple agreements across four U.S. geographies.
- Cash position strengthened to $8.7 million as of June 30, 2026, with net operating cash outflow expected to be below $14.0 million for the full year.
The big picture
HeartBeam is positioning itself as a disruptor in the cardiac care space by accelerating its heart attack detection program and expanding its commercial footprint. The company's strategic focus on real-world validation and cost efficiency aligns with broader industry trends toward personalized, ambulatory cardiac monitoring solutions. With a strengthened cash position and key milestones ahead, HeartBeam aims to capture significant market share in both the U.S. and international markets.
What we're watching
- Regulatory Pathway
- Whether HeartBeam can secure FDA approval for heart attack assessment indication based on upcoming study results.
- Commercial Traction
- The pace at which HeartBeam can scale its commercial launch across targeted U.S. geographies and onboard new practices.
- Strategic Partnerships
- How potential partnerships for the 12-lead ECG patch could accelerate market penetration in the $2 billion ambulatory cardiac monitoring space.